SCHEMBL823734

SCHEMBL823734

COCCOc1nc(N)nc2ccc(-c3ccc(C(=O)NOC)cc3)nc12

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MKNK2 Q9HBH9 7/20 0.41
MKNK1 Q9BUB5 6/20 0.41
LOXL2 Q9Y4K0 1/20 0.37
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
PIK3CA P42336 1/20 0.36
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
MAP4K4 O95819 2/20 0.35
CHEK2 O96017 1/20 0.34
TSHR P16473 1/20 0.34
BRAF P15056 1/20 0.34
PDE4A P27815 1/20 0.33
PDE4B Q07343 1/20 0.33
PDE4C Q08493 1/20 0.33
PDE4D Q08499 1/20 0.33
PARP1 P09874 1/20 0.33
ATR Q13535 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL823761 0.90 MKNK2 (0.38) MKNK2MKNK1NPC1RAB9ASMN1; SMN2
SCHEMBL823773 0.90 MKNK2 (0.46) MKNK2MKNK1LOXL2MAP4K4
SCHEMBL823609 0.87 MKNK1 (0.46) MKNK2MKNK1NPC1RAB9ASMN1; SMN2
SCHEMBL823644 0.85 NPC1 (0.42) NPC1RAB9ASMN1; SMN2PIK3CAKDM4E
SCHEMBL4519618 0.84 PIK3CG (0.40) NPC1PIK3CAMAP4K4TSHR
SCHEMBL823688 0.84 PDE4A (0.40) MKNK2MKNK1SMN1; SMN2PIK3CAKDM4E
SCHEMBL4521670 0.84 MEN1 (0.44) PIK3CAKDM4EALDH1A1PDE4APDE4B
SCHEMBL4516860 0.84 MAPT (0.41) NPC1RAB9ASMN1; SMN2PIK3CAKDM4E
SCHEMBL823724 0.84 MKNK2 (0.38) MKNK2MKNK1MAP4K4BRAFPDE4A
SCHEMBL826145 0.84 MKNK2 (0.36) MKNK2MKNK1KDM4EMAP4K4PDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090324543-A1 PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC (US) 2009-12-31 US claimed
US-8143394-B2 Pyrido(3,2-d)pyrimidines useful for treating viral infections GILEAD SCIENCES, INC. (US) 2012-03-27 US disclosed
US-8143394-B2 Pyrido(3,2-d)pyrimidines useful for treating viral infections GILEAD SCIENCES, INC. (US) 2012-03-27 US disclosed
US-8143394-B2 Pyrido(3,2-d)pyrimidines useful for treating viral infections GILEAD SCIENCES, INC. (US) 2012-03-27 US disclosed
US-20090324543-A1 PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC (US) 2009-12-31 US disclosed
US-20090324543-A1 PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC (US) 2009-12-31 US disclosed
US-20090324543-A1 PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC (US) 2009-12-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090324543-A1 PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS PNPO, DPYD, PLPBP MKNK2 3173/4885MKNK1 3271/4885LOXL2 2335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.